细胞因子信号传导抑制蛋白-3在前列腺癌中作用的研究进展

李晟; 王大文; 朱诗建; 木海琦; 杨森; 南存金; 张磊; 陈映鹤

doi:10.13201/j.issn.1001-1420.2014.09.032

细胞因子信号传导抑制蛋白-3在前列腺癌中作用的研究进展

- 温州医科大学附属第二医院泌尿外科(浙江温州, 325027)

详细信息

通讯作者: 陈映鹤,E-mail:chenyh@wzhealth.com

中图分类号: R737.25

收稿日期: 2014-06-11

Research progress of suppressor of cytokine signaling-3 in prostate cancer

- Department of Urology, Second Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, 325027, China

More Information

Corresponding author: CHEN Yinghe, E-mail: chenyh@wzhealth.com

Received Date: 11 June 2014

摘要

摘要: 细胞因子信号抑制蛋白-3（suppressor of cytokine signaling-3，SOCS-3）是一种很常见的抑制性信号调节蛋白，可参与负反馈调节Janus激酶、转录激活因子（JAK/STAT）及信号转导等多种重要信号通路，从而调控细胞因子、生长因子等对细胞的作用。SOCS-3可通过多种机制调节前列腺癌细胞的迁移及侵袭能力。本文主要就SOCS-3在这一方面的研究进展作一简单综述。
- 前列腺癌 /
- 细胞因子信号传导抑制蛋白-3 /
- 肿瘤侵袭与转移
Abstract: The suppressor of cytokine signaling-3 (SOCS-3) is a common inhibitory signal regulatory protein. It can participate in the negative feedback regulation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) and other important signaling pathways, so as to regulate role of cytokines and growth factors on cells. Migration and invasion ability of prostate cancer cells can be regulated by SOCS-3 through a variety of mechanisms. This paper will provide a brief review on it.
- prostate cancer /
- suppressor of cytokine signaling-3 /
- tumor invasion and metastasis

HTML全文

参考文献(20)

[1]	江先汉,毕学成,何慧婵,等. 前列腺癌与良性前列腺增生中NFKBIA及SREBF2的表达[J]. 中华实验外科杂志, 2010, 26(3):328-329.
[2]	王国民,武睿毅. 我国前列腺癌实验研究的现状和展望[J]. 中华实验外科杂志, 2006, 22(9):1031-1034.
[3]	Puhr M, Santer F R, Neuwirt H, et al. SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling[J]. Endocrine-Related Cancer, 2010, 17(2):525-538.
[4]	Zhu J, Dai Q, Han Z, et al. Expression of SOCSs in human prostate cancer and their association in prognosis[J]. Mol Cell Biochem, 2013, 381(1-2):51-59.
[5]	Weber A, Hengge U R, Bardenheuer W, et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition[J]. Oncogene, 2005, 24(44):6699-6708.
[6]	Wu W Y, Kim H, Zhang C L, et al. Loss of suppressors of cytokine signaling 3 promotes aggressiveness in hepatocellular carcinoma[J]. J Invest Surg, 2014, 27(4):197-204.
[7]	Kumar J, Ward A C. Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications[J]. Biochim Biophys Acta, 2014, 1845(2):117-125.
[8]	Chandra R A, Chen M H, Zhang D, et al. Evidence suggesting that obesity prevention measures may improve prostate cancer outcomes using data from a prospective randomized trial[J]. Prostate Cancer, 2014, 2014:478983.
[9]	He B, You L, Uematsu K, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer[J]. Proc Natl Acad Sci U S A, 2003, 100(24):14133-14138.
[10]	Kovarik A, Fojtova M, Boudny V, et al. Interferon-γ, but not interferon-α, induces SOCS 3 expression in human melanoma cell lines[J]. Melanoma Research, 2005, 15(6):481-488.
[11]	Lesinski G B, Zimmerer J M, Kreiner M, et al. Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells[J]. BMC Cancer, 2010, 10(1):142.
[12]	Stofas A, Levidou G, Piperi C, et al. The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma[J]. BMC Cancer, 2014, 14(1):149.
[13]	Chandra R A, Chen M H, Zhang D, et al. Evidence suggesting that obesity prevention measures may improve prostate cancer outcomes using data from a prospective randomized trial[J]. Prostate Cancer, 2014, 2014:478983.
[14]	Koskinen A, Vuolteenaho K, Korhonen R, et al. SOCS-3 expression in the cartilage is reduced in obese patients with osteoarthritis and regulates leptin responses in chondrocytes[J]. Osteoarthritis and Cartilage, 2013, 21:S231-S231.
[15]	Kneitz B, Krebs M, Kalogirou C, et al. Survival in high-risk prostate cancer patients is predicted by mir-221, which regulates proliferation, apoptosis and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3[J]. Cancer Res, 2014, 74(9):2591-603.
[16]	Pierconti F, Martini M, Pinto F, et al. Epigenetic silencing of SOCS-3 identifies a subset of prostate cancer with an aggressive behavior[J]. The Prostate, 2011, 71(3):318-325.
[17]	Zhang C, Zhang J, Hao J, et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma[J]. J Transl Med, 2012, 10:119.
[18]	Collins A S, Ahmed S, Napoletano S, et al. Hepatitis C virus (HCV)-induced suppressor of cytokine signaling (SOCS) 3 regulates proinflammatory TNF-α responses[J]. J Leukoc Biol, 2014, 96(2):255-263.
[19]	Sasi W, Jiang W G, Sharma A, et al. Higher expression levels of SOCS 1, 3, 4, 7 are associated with earlier tumour stage and better clinical outcome in human breast cancer[J]. BMC Cancer, 2010, 10(1):178.
[20]	Kelly W K, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer:CALGB 90401[J]. J Clin Oncol, 2012, 30(13):1534-1540.